<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Our previous study showed that pretreatment with <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> via opening of the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ATP-sensitive <z:chebi fb="120" ids="26216">potassium</z:chebi> channel protects myocardium against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injuries </plain></SENT>
<SENT sid="1" pm="."><plain>We have hypothesized that production of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) and generation of reactive oxygen species (ROS) are involved in <z:chebi fb="15" ids="33569">noradrenaline</z:chebi>-induced cardioprotection in rat heart </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:hpo ids='HP_0000001'>All</z:hpo> anesthetized rats underwent 25 min of regional <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> followed by 120 min of reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>Animals were randomized to receive one of the following treatment: saline, <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> (2 μg/kg, i.v.), <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> plus <z:chebi fb="1" ids="8364">prazosin</z:chebi> (an α(1)-adrenoceptor blocker, 0.5mg/kg, i.v.), <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> plus L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (a nonspecific NOS inhibitor, 10mg/kg, i.v.), <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> plus tempol (a membrane-permeable radical scavenger, 30 mg/kg, i.v.), <z:chebi fb="1" ids="8364">Prazosin</z:chebi> alone, only L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> and tempol alone </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:mpath ids='MPATH_124'>Infarct</z:mpath> size (% of risk area) was reduced from 49.6 ± 2.4 in saline-control group to 18.2 ± 1.5 in <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> preconditioned group </plain></SENT>
<SENT sid="5" pm="."><plain>Administration of <z:chebi fb="1" ids="8364">prazosin</z:chebi>, L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>, or tempol prior to <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> injection abolished the observed cardioprotection of <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> (45.5 ± 3, 41.7 ± 4.5 and 38.7 ± 5.4, respectively) and restored <z:mpath ids='MPATH_124'>infarct</z:mpath> size to saline-control rats' level </plain></SENT>
<SENT sid="6" pm="."><plain>Incidences and severity of <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and early reperfusion significantly decreased in <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> preconditioned group compared with saline-control group </plain></SENT>
<SENT sid="7" pm="."><plain>This cardioprotective effect of <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> against <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> was abrogated by administration of <z:chebi fb="1" ids="8364">prazosin</z:chebi>, L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>, or tempol </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Cardioprotection effect of the α(1)-adrenoceptor stimulation by <z:chebi fb="15" ids="33569">noradrenaline</z:chebi> was inhibited by L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> or tempol in anesthetized rat heart </plain></SENT>
</text></document>